<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药筛 | wechat-feeds</title><link>http://Mzg5NTI5ODYzOA.favicon.privacyhide.com/favicon.ico</link><description>药品筛选</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 11 Apr 2021 19:19:32 +0800</pubDate><image><url>http://Mzg5NTI5ODYzOA.favicon.privacyhide.com/favicon.ico</url><title>药筛 | wechat-feeds</title><link>http://Mzg5NTI5ODYzOA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>新批文数稳定，仿制药申报减少，阿哌沙班等畅销品种竞争加剧  | 3月仿制药动态</title><link>https://mp.weixin.qq.com/s/psEpsPiHFmwuDF1r5SesPw</link><description></description><content:encoded><![CDATA[新批文数稳定，仿制药申报减少，阿哌沙班等畅销品种竞争加剧  | 3月仿制药动态]]></content:encoded><pubDate>Sun, 11 Apr 2021 19:18:45 +0800</pubDate></item><item><title>集采后，扬子江药业右美托咪定一家独大，还能维持多久</title><link>https://mp.weixin.qq.com/s/d-U5LBfBxsRYr3nuXo5Urw</link><description></description><content:encoded><![CDATA[集采后，扬子江药业右美托咪定一家独大，还能维持多久]]></content:encoded><pubDate>Thu, 08 Apr 2021 20:46:13 +0800</pubDate></item><item><title>集采两年后，培美曲塞市场销售有何变化？</title><link>https://mp.weixin.qq.com/s/dmpGYfdXGBlF6JkX74zeHQ</link><description></description><content:encoded><![CDATA[集采两年后，培美曲塞市场销售有何变化？]]></content:encoded><pubDate>Wed, 07 Apr 2021 22:28:41 +0800</pubDate></item><item><title>石药欧意 两性霉素B胆固醇硫酸酯复合物获批上市 | 上周仿制药动态（3.29-4.5）</title><link>https://mp.weixin.qq.com/s/L-QH_VLwTJ-5U9Jr6A1VjA</link><description></description><content:encoded><![CDATA[石药欧意 两性霉素B胆固醇硫酸酯复合物获批上市 | 上周仿制药动态（3.29-4.5）]]></content:encoded><pubDate>Tue, 06 Apr 2021 15:54:44 +0800</pubDate></item><item><title>恒瑞、齐鲁 多西他赛注射液过评价 | 上周仿制药动态（3.22-3.28）</title><link>https://mp.weixin.qq.com/s/DsAhn55_2rvoGLcIT4n5dA</link><description></description><content:encoded><![CDATA[恒瑞、齐鲁 多西他赛注射液过评价 | 上周仿制药动态（3.22-3.28）]]></content:encoded><pubDate>Mon, 29 Mar 2021 20:01:26 +0800</pubDate></item><item><title>不经意间，头孢类品种已有154个批文过评价（附目录）</title><link>https://mp.weixin.qq.com/s/zFalYXct-thLlwF4DCEFew</link><description></description><content:encoded><![CDATA[不经意间，头孢类品种已有154个批文过评价（附目录）]]></content:encoded><pubDate>Thu, 25 Mar 2021 19:09:45 +0800</pubDate></item><item><title>海南普利 地氯雷他定独家剂型过评价 | 上周仿制药动态（3.15-3.21）</title><link>https://mp.weixin.qq.com/s/iasqKIGxTYB49lGuGKJY-A</link><description></description><content:encoded><![CDATA[海南普利 地氯雷他定独家剂型过评价 | 上周仿制药动态（3.15-3.21）]]></content:encoded><pubDate>Mon, 22 Mar 2021 16:44:46 +0800</pubDate></item><item><title>3个独家剂型品种过评价</title><link>https://mp.weixin.qq.com/s/e__LGlTRmXVm9EukfHPE-A</link><description></description><content:encoded><![CDATA[3个独家剂型品种过评价]]></content:encoded><pubDate>Wed, 17 Mar 2021 18:05:52 +0800</pubDate></item><item><title>尼达尼布、培美曲塞、地西他滨等多款抗肿瘤药过评价 | 上周仿制药动态（3.8-3.14）</title><link>https://mp.weixin.qq.com/s/bMLYq1NB33s8vr7Ei_iwNA</link><description></description><content:encoded><![CDATA[尼达尼布、培美曲塞、地西他滨等多款抗肿瘤药过评价 | 上周仿制药动态（3.8-3.14）]]></content:encoded><pubDate>Mon, 15 Mar 2021 16:37:20 +0800</pubDate></item><item><title>齐鲁又一特色品种获批，机会or挑战？</title><link>https://mp.weixin.qq.com/s/8nWEZxE3_0q3dGPy4Q2W8w</link><description></description><content:encoded><![CDATA[齐鲁又一特色品种获批，机会or挑战？]]></content:encoded><pubDate>Thu, 11 Mar 2021 19:25:18 +0800</pubDate></item></channel></rss>